Anthrogenesis Corporation, a division of Celgene, is awarded yet another U.S. patent for inventions related to methods of deriving adult stem cells from human placentas.
A U.S. doctor has been invited to visit China as part of a fact-finding mission on the current state of stem cell therapies that are only available outside of the United States.
The stem cell company Neuralstem has filed an application with the FDA to begin the first clinical trials ever to be conducted with adult stem cells in the treatment of amyotrophic lateral sclerosis.
The U.S. Food and Drug Administration has granted marketing approval for Mozobil, Genzyme’s patented drug which stimulates the mobilization of autologous adult stem cells, now available for the treatment of non-Hodgkin’s lymphoma and multiple myeloma.
A 2-year-old infant improves after receiving an autologous adult stem cell treatment for dilated cardiomyopathy.
A new publication issued by the Vatican has high praise for adult stem cell research and therapies, but not for embryonic stem cell research.
Toll Free:
1-800-980-STEM (7836)
Outside or Inside US Call:
1-954-358-3382
Toll Free Fax (US Only):
1-866-755-3951
From Outside US Fax:
1-775-887-1194
Copyright 2024, Stem Cell Insitute Panama. All rights reserved.
